An exploratory phase II, multicenter, open-label trial evaluating the activity and tolerability of FK228 in androgen independent metastatic prostate cancer patients with rising PSA

Trial Profile

An exploratory phase II, multicenter, open-label trial evaluating the activity and tolerability of FK228 in androgen independent metastatic prostate cancer patients with rising PSA

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2014

At a glance

  • Drugs Romidepsin (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Nov 2006 Status change
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top